• Reduction of the initial HAM-D by 50% or more at week 9 of the trial [ Time Frame: 9 Weeks ]
  
• Reduction of the HAM-D score to less than or equal to 7 at week 9 [ Time Frame: 9 Weeks ]
  
• Change of CGI score achievement to "very much improved" or "much improved" at week 9 [ Time Frame: 9 Weeks ]
  
• A 50% decrease in the GCS at week 9. [ Time Frame: 9 Weeks ]
  

Inclusion Criteria:

• Women age 40 years old or older.
• Perimenopausal symptoms of at least 3 months duration, including irregular periods and/or hot flashes.
• Minimum score of 15 on the Hamilton Rating Scale for Depression (17-item).
• Subjects must be able to be treated on an outpatient basis.
• Subjects must be able to provide written informed consent.

Exclusion Criteria:

• Subjects presently taking antidepressant medication.
• Subjects currently using hormone replacement therapy.
• Subjects who are pregnant.
• Subjects who have hepatic disease.
• Other Axis I disorders, except Generalized Anxiety Disorder or Panic Disorder.
• "Uncontrolled" narrow angle glaucoma.
• Known hypersensitivity to duloxetine or any of the inactive ingredients.
• Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of study drug administration or potential need to use an MAOI during the study or within 5 days of discontinuation of study drug.
• Presence of psychotic symptoms.
• History of mania or hypomania.
• Hamilton Rating Scale for Depression (HAM-D) suicide item score > 2.
• End stage renal disease or severe renal impairment.
• Abnormal uterine bleeding that has not been evaluated by a gynecologist (heavy or prolonged uterine bleeding, menstrual periods occurring more frequently than every 3 weeks, bleeding after sexual intercourse, spotting between periods).